Skip to content
Subscriber Only

Gilead’s Remdesivir Mainly Helped Healthier Covid-19 Patients

  • Remdesivir patients recovered in 11 days vs 15 on placebo
  • Patients with more severe virus cases saw little benefit
A vial of Remdesivir

A vial of Remdesivir

Photographer: Ulrich Perrey/AFP via Getty Images

Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.

Gilead Sciences Inc.’s remdesivir, the first medicine cleared for the treatment of Covid-19, mainly benefited healthier patients who weren’t dependent on ventilators or heart-lung bypass machines, according to published results of the study used to get the medicine on the market.